Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer

Exclusion Criteria

• •Evidence of distant metastatic disease and other oropharyngeal cancers
• •Surgical procedure of the primary tumor or lymph nodes (except diagnostic biopsy) before study treatment
• •Previous radiotherapy for the primary tumor or lymph nodes
• •Previous exposure to epidermal growth factor - targeted therapy
• •Prior chemotherapy or immunotherapy for the primary tumor
• •Other previous malignancy within 5 years, except adequately treated non-melanoma skin cancer or pre-invasive carcinoma of the cervix
• •Any investigational agent prior to the 1st study medication
• •Participation in another clinical study within the 30 days prior to Inclusion in this study.
• •Peripheral neuropathy \> grade 1
• •Known grade 3 or 4 allergic reaction to any of the study treatment
• •Creatinine Clearance \< 30 ml/min
• •Know drug abuse / alcohol abuse
• •Legal incapacity or limited legal capacity
• •Active systemic infection
• •Medical or psychiatric illness, which in the investigators' opinions, would not permit the subject to complete or fully and completely understand the risks and potential complications of the study
• •Concurrent chronic systemic immune therapy or hormone therapy not indicated in the study protocol
• •Pregnancy (confirmed by serum or urine β-HCG) or lactation period
• •Severe cardiac disease such as heart failure, clinically relevant cardiac dysrhythmias, coronary artery disease or myocardial infarction within the last 12 months